Horizon Therapeutics (NAS:HZNP) GF Value Rank

: 5 (As of Today)

View and export this data going back to 2011. Start your Free Trial

Horizon Therapeutics has the GF Value Rank of 5.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Horizon Therapeutics GF Value Rank Distribution

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's GF Value Rank falls in comparison to its industry or sector. The grey bar indicates the GF Value Rank's extreme value range as defined by GuruFocus.

Horizon Therapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Horizon Therapeutics (NAS:HZNP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (NAS:HZNP) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

HZNP:Mexico HPR:Germany

Address

70 St. Stephen’s Green, Dublin, IRL, D02 E2X4

Website

https://www.horizontherapeutics.com

Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.

Executives

Patrick Mcilvenny	officer: Chief Accounting Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Jacopo Leonardi	officer: Chief Commercial Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Aaron Cox	officer: EVP, Chief Financial Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Sean M. Clayton	officer: EVP, General Counsel	C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4
Thompson Elizabeth H.z.	officer: EVP, Research & Development	C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Karin Rosen	officer: EVP, R&D & CSO	C/O HORIZON THERAPEUTICS, INC., CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Daniel A. Camardo	officer: EVP and President, U.S.	ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Andy Pasternak	officer: EVP and Chief Business Officer	C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jeff Kent	officer: See remarks	C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 4
Shao-lee Lin	officer: EVP, Head of R&D and CSO	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Irina Konstantinovsky	officer: EVP, Chief Human Resources Off	C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 4
Eric Mosbrooker	officer: SVP, Orphan Business Unit	C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000
Pascale Witz	director	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
James Samuel Shannon	director	28903 NORTH AVENUE PAINE, VALENCIA CA 91355